MicroRNA-21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: An in vitro study

Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma

(2017) Kelly Gaudelot et al.   TUMOR BIOLOGY

In vitro assessment of anti-proliferative effect induced by α-mangostin from Cratoxylum arborescens on HeLa cells

(2017) Aisha I. El habbash et al.   PeerJ

Antisense oligonucleotides against microRNA-21 reduced the proliferation and migration of human colon carcinoma cells

(2015) Yi-Jing Tao et al.   Cancer Cell International

The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells

(2015) Ryan Charles Pink et al.   GYNECOLOGIC ONCOLOGY

Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy

(2015) Hojung Song et al.   JOURNAL OF DRUG TARGETING

Expression and clinicopathological significance of microRNA-21 and programmed cell death 4 in malignant melanoma

(2015) Jian Jiao et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis

(2015) Mitchell S. Stark et al.   EBioMedicine

The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options

(2015) Emmanuel Gabriel et al.   Cancers

MiR-21 Enhances Melanoma Invasiveness via Inhibition of Tissue Inhibitor of Metalloproteinases 3 Expression: In Vivo Effects of MiR-21 Inhibitor

(2015) Sara E. Martin del Campo et al.   PLoS One

Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients

(2014) Nathaniel H. Fleming et al.   CANCER

Wnt5a/Ca2+/calcineurin/nuclear factor of activated T signaling pathway as a potential marker of pediatric melanoma

(2014) Qiufang Qian et al.   Journal of Cancer Research and Therapeutics

The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion

(2014) Nina Petrović et al.   MEDICAL ONCOLOGY

miR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4

(2014) Wenhao Ren et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Downregulation of miR-21 Enhances Chemotherapeutic Effect of Taxol in Breast Carcinoma Cells

(2014) Mei Mei et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

WP1066 Sensitizes Oral Squamous Cell Carcinoma Cells to Cisplatin by Targeting STAT3/miR-21 axis

(2014) Xuan Zhou et al.   Scientific Reports

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

(2013) J. D. Wolchok et al.   ANNALS OF ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

MicroRNA-21 in Pancreatic Ductal Adenocarcinoma Tumor-Associated Fibroblasts Promotes Metastasis

(2013) Brian E. Kadera et al.   PLoS One

miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN

(2013) Shou-mei Yang et al.   TOXICOLOGY

Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth

(2012) Yan-Xia Zhang et al.   BIOMEDICINE & PHARMACOTHERAPY

Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors

(2012) Y Xu et al.   BRITISH JOURNAL OF CANCER

microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells

(2012) Imke Satzger et al.   EXPERIMENTAL DERMATOLOGY

Human Circulating MicroRNA-1 and MicroRNA-126 as Potential Novel Indicators for Acute Myocardial Infarction

(2012) Guangwen Long et al.   International Journal of Biological Sciences

The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma

(2011) Li Jiang et al.   ACTA HISTOCHEMICA

MicroRNA-21: A novel therapeutic target in human cancer

(2011) Xuan Pan et al.   CANCER BIOLOGY & THERAPY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival

(2010) M. F. Segura et al.   CLINICAL CANCER RESEARCH

Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line

(2010) Haitao Bai et al.   FEBS LETTERS

Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells

(2010) Haiyan Hu et al.   LEUKEMIA & LYMPHOMA

Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase

(2010) T.-H. Kang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation

(2009) Brigitte Lankat-Buttgereit et al.   BIOLOGY OF THE CELL

MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme

(2009) Yiming Li et al.   BRAIN RESEARCH

MicroRNAs in Cancer: Small Molecules With a Huge Impact

(2009) Marilena V. Iorio et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells

(2008) T. Papagiannakopoulos et al.   CANCER RESEARCH